Collin Chin

Clinical Associate Professor Collin Chin is a Clinician Researcher and Consultant Haematologist at The University of Western Australia (UWA Medical School, Department of Internal Medicine), with clinical appointments at Royal Perth Hospital (Lymphoma Lead), Cell & Tissue Therapies WA, and Rockingham General Hospital.

His academic qualifications include:

• MBBS (Hons) from The University of Western Australia (2012)
• Clinical Haematology, FRACP, Royal Australasian College of Physicians (2020)
• Laboratory Haematology, FRCPA, Royal College of Pathologists of Australasia (2020)

Professor Chin's research centers on advancing treatments for B-cell lymphomas through immune effector cell therapies. His work specifically targets optimizing CAR T-cell therapy and bispecific antibodies for Australian patients, with strong emphasis on overcoming accessibility barriers in outer metropolitan and rural healthcare settings. Current investigations focus on treatment efficacy, toxicity management (particularly cytokine release syndrome and neurologic events), and real-world implementation of novel lymphoma therapies.

Recent publications demonstrate a clear trend toward solving practical delivery challenges in community hospital environments, analyzing post-CAR-T relapse scenarios, and evaluating next-generation immunotherapies like Epcoritamab. The work bridges clinical trials with frontline practice to improve lymphoma outcomes across diverse healthcare infrastructures.

His scientific recognition includes:

• Raine Foundation Clinician Research Fellowship (2024) for developing place-of-care CAR T-cell therapy manufacturing in Western Australia

Professor Chin actively supervises junior doctors and medical students at UWA while securing over $1.5 million in competitive research funding. His leadership in the Royal Perth Hospital Lymphoma Service drives translational research from bench to bedside, focusing on bringing breakthrough cellular therapies to Australian patients through strategic collaborations.

He leads the Lymphoma program at Royal Perth Hospital and partners with Cell & Tissue Therapies WA to establish decentralized CAR T-cell therapy manufacturing capabilities across Western Australia.